Panacea Biotec Ltd. - Research Center
531349 PANACEABIO Group (B) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Sep ' 22 | Mar ' 22 | Sep ' 21 | Sep ' 20 | Mar ' 20 | |
|---|---|---|---|---|---|
| Sales | 110.08 | 79.98 | 155.52 | 194.68 | 112.29 |
| Operating profit | -78.34 | -35.82 | -36.86 | 13.34 | -17.91 |
| Interest | 4.68 | 3.35 | 3.69 | 3.77 | 3.51 |
| Gross profit | -68.57 | -34.22 | -32.93 | 15.39 | 7.54 |
| EPS (Rs) | -13.23 | -7.79 | -7.48 | 0.32 | -8.52 |
Half yearly
results in details
| Sep ' 22 | Mar ' 22 | Sep ' 21 | Sep ' 20 | Mar ' 20 | |
|---|---|---|---|---|---|
| Other income | 14.45 | 4.95 | 7.62 | 5.82 | 28.96 |
| Stock adjustment | 37.38 | -12.41 | -48.54 | 6.82 | -8.82 |
| Raw material | 66.50 | 38.42 | 133.98 | 36.76 | 43.54 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 34.51 | 37.32 | 35.18 | 27.07 | 25.85 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 50.03 | 52.47 | 71.76 | 110.69 | 69.63 |
| Provisions made | - | - | - | - | - |
| Depreciation | 12.52 | 13.52 | 12.91 | 13.36 | 13.11 |
| Taxation | - | - | - | 0.03 | 12.14 |
| Net profit / loss | -81.09 | -47.74 | -45.84 | 1.97 | -52.22 |
| Extra ordinary item | - | - | - | -0.03 | -34.51 |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 6.13 | 6.13 | 6.13 | 6.13 | 6.13 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | -71.17 | -44.79 | -23.70 | 6.85 | -15.95 |
| GPM (%) | -55.06 | -40.29 | -20.19 | 7.68 | 5.34 |
| NPM (%) | -65.12 | -56.21 | -28.10 | 0.98 | -36.97 |
Mutual Fund Selector
Find the fund that is right for you
© 2023 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis